For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
Statin non-use and the nocebo effect: How can your patient’s reticence be overcome?
+Practice
In print
HEARTBEAT
Statin non-use and the nocebo effect: How can your patient’s reticence be overcome?
Wednesday 3 March 2021, 12:25 AM

Consultant cardiologist Chris Ellis discusses how to address a patient’s concerns about statin side effects, and the evidence and strategies useful to reassure them
Key points, Significant and harmful rhabdomyolysis with statin use is very rare.
Between 85 and 95 per cent of patients using a statin have no difficulty with , Pract Green w Pale Yellow
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.
References
- Nissen SE, Stroes E, Dent-Acosta RE, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: The GAUSS-3 randomized clinical trial. JAMA 2016;315(5):1580–90.
- Wood FA, Howard JP, Finegold JA, et al. N-of-1 trial of a statin, placebo, or no treatment to assess side effects. N Engl J Med 2020;383(22):2182–84.